INTRODUCTION
Inflammatory rheumatic diseases are a group of systemic disorders with a chronic course and with an unknown etiopathogenesis. Recent studies have implicated environmental factors and genetic background in the etiology of inflammatory rheumatic diseases. 1, 2 The ABO blood type system was described many years ago 3 , and there are four main blood types depending on the presence of A and B antigens: A, B, AB and O. 4 In the Rhesus system, blood is classified as either Rh (-) or Rh (+) according to the presence of Rhesus D antigen on the surface of the red blood cells. 5 The ABO and Rh blood groups are used in clinical practice, although numerous other blood groups have been identified related to the presence of different antigens. The frequency of distribution of the ABO and Rh blood groups varies between races. O blood group is more common around the world 6 , although studies have reported higher frequency rates of the A and Rh (+) blood groups in Turkey. 7, 8 ABO antigens are complex carbohydrate molecules that are expressed on the surfaces of red blood cells, but also on the epithelium, neurons, platelets, and vascular endothelial cells. 9,10 The ABO gene system, therefore, controls a certain proportion of the carbohydrate repertoire. 11, 12 These carbohydrates possess a variable structural diversity, but also act as a potential receptor for the pathogenic and nonpathogenic microorganisms that are involved in infections and susceptibility to, or resistance against, diseases. 12, 13 This raises the possibility that ABO antigens may play a role in the pathogenesis of various diseases. Previous studies have demonstrated a possible link between the ABO and Rh blood groups and such diseases as diabetes, cancer, cardiovascular disease and infection. [14] [15] [16] It has been asserted that the ABO antigen system plays a role in the pathogenesis of these disorders through the Von Willebrand factor and various proinflammatory and adhesion molecules. 17, 18 Similarly, proinflammatory cytokines and adhesion molecules, together with genetic background, have been implicated in the pathogenesis of rheumatic diseases. [19] [20] [21] Due to the involvement of similar mechanisms in the pathogenesis, the authors suggest that a relationship may exist between the ABO antigen system and rheumatic disease, although there have been only a limited number of studies in the literature evaluating the relationship between inflammatory rheumatic disease and blood types. This relationship continues to be poorly understood due to the lack of a control group in studies reported in literature, and to the best of our knowledge, there has been no study conducted to date on Turkish patients comparing the distribution of blood types in patients with inflammatory rheumatic diseases with that of healthy controls. The aim of the present study is, therefore, to compare the distribution of ABO and Rh blood types between patients with various inflammatory rheumatic diseases with that of healthy controls.
MATERIAL AND METHODS
The present study evaluated retrospectively the records of 1500 patients who were followed up at our clinic due to inflammatory rheumatic disease ( [SjS] and gout) between June 2016 and January 2019, and of whom blood groups were available (Group 1), and those of 1272 healthy blood donors (Group 2). The past medical histories of the patients with inflammatory rheumatic disease to be included in the study were reviewed, and aside from inflammatory rheumatic disease, patients with autoimmune, inflammatory, endocrine, gastrointestinal and hematological disorders, and patients with cancer, chronic infection and cardiovascular disease that were previously evaluated for their relationship with the blood types were excluded from the study. The gender, type of rheumatic disease, and ABO and Rh blood groups of the participants were recorded.
The study was approved by the Human Ethics Committee of our University and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
Statistical analyses
Analyses were conducted with the IBM SPSS Statistics 22 (IBM Corp., Armonk, NY, USA). The data are presented as percentages. A Chi-Square test was used to evaluate the categorical data. In logistic regression analysis, the gender, ABO and Rh blood group data entered into the model. A pvalue of <0.05 was considered statistically significant.
RESULTS
The study was conducted on the data of 1272 healthy subjects and 1028 patients with an inflammatory rheumatic disease who met the study inclusion criteria (Diagram 1). Group 1 comprised 395 (38.4%) males and 633 (61.6%) females, and Group 2 comprised 1198 (94.2%) males and 74 (5.8%) females. Gender distribution was not homogeneous between the groups (p<0.05). Distribution of the ABO blood type was similar between the two groups. However, the Rh (+) blood type was more prevalent in patients with rheumatic disease when compared to the healthy control group, and the difference was statistically significant (p<0.05). The distribution of the ABO and Rh blood types in the two groups are presented in Table 1 . When the present rheumatic diseases were evaluated in terms of the distribution of ABO blood groups, the A and O blood groups were equally distributed among patients with SLE, the O blood group was more prevalent in patients with gout, whereas the A blood group was more prevalent in patients with other inflammatory rheumatic diseases, although the findings in this regard were not statistically significant (p>0.05) ( Table 2 ). When rheumatic diseases were evaluated in terms of the distribution of the Rh blood group, Rh (+) was more prevalent in all rheumatic diseases, although there was no significant difference between the groups of rheumatic diseases in terms of Rh blood group distribution (p>0.05) ( Table 3 ). According to the results of logistic regression analysis, the Rh (-) blood type decreases the likelihood of developing a rheumatic disease (p<0.05) ( Table 4 ). 
Diagram 1: Flow diagram of the selection process for the patient groups

DISCUSSION
The present study found that the A and Rh (+) blood groups were more prevalent in patients with inflammatory rheumatic disease and the A blood group was followed by O, B, and AB blood groups, in respective order. However the present study found that the distribution of ABO blood groups in patients with inflammatory rheumatic disease was no different to that of the healthy controls, although the Rh (+) blood group was more prevalent in patients with inflammatory rheumatic disease than in the healthy controls. In addition, the present study also found that individuals with Rh (-) blood type are less likely to develop a rheumatic disease.
To our knowledge the present study is the first in the literature to report such findings.
Genetic factors may play a role in the development and prognosis of certain diseases. Blood groups are inherited and are not affected by environmental factors. 3 Blood groups have been evaluated as hematological markers in various studies, and clinical studies have demonstrated a relationship between the ABO and Rh blood groups and various types of cancer, diabetes, and cardiovascular diseases. 4, 17, 22 Although this has not been clarified, it is suggested that different mechanisms may be involved in the role played by ABO antigens in the pathogenesis of these diseases. 17, 18, 23 Previous clinical studies have shown that various genetic and environmental factors play a role in the etiology of inflammatory rheumatic disease. 1, 24, 25 HLA genes, in particular, have been implicated in the pathogenesis of several rheumatic diseases (i.e. HLA-DRB1 and HLA-DP1 in RA, HLA-B27 in SpA, and HLA-B51 in BH. [26] [27] [28] On the other hand, there are studies in literature identifying a possible relationship between HLA and ABO antigens. 29, 30 There are a limited number of studies in literature evaluating the distribution of blood types in patients with rheumatic disease, and the results of the few studies that do exist are variable. Stoia et al. 31 reported that the A blood type is more prevalent in a study involving patients with RA and AS. Another study, conducted by Shinebaum 32 , reported a higher prevalence rate of the O blood type among patients with SpA, while a further study reported a higher prevalence rate of the A blood type in patients with discoid lupus erythematosus. 33 Ozyurt et al. 34 identified a higher rate of O and Rh (+) blood types in patients with BD. In a recent study involving no control group, A and Rh (+) blood types were found to be more prevalent among patients with RA, SpA, BD, UCTD and vasculitis, whereas O and Rh (-) blood types were found to be more common in patients with SLE, SSc and SjS. 24 The present study found the A and Rh (+) blood types to be generally more prevalent in patients with inflammatory rheumatic disease. Previous studies have reported both similar and opposing results, ad similarly, the present study reports similar and opposing results compared to those reported in previous studies. The prevalence rates of blood types differ across nations, races, and regions. 36 The differences between the results of the present study and those of previous studies may be attributed to the differences in the genetic basis of inflammatory rheumatic diseases.
One limitation of the present study that it was not conducted on a large patient population, that no genetic analysis was made of the patients, that the patient and control groups included in the study were from a single-center and gender distribution was not homogeneous between the groups.
In conclusion, the A and Rh (+) blood types were more commonly observed in inflammatory rheumatic disease, followed by the O, B, and AB blood types. Furthermore, patients with the Rh (-) blood type were less likely to develop rheumatic disease. The present study may serve as a guide for future clinical studies evaluating the relationship between rheumatic diseases and blood types in terms of genetic predisposition and pathogenesis. Further multicenter clinical studies involving larger patient groups, and that evaluate the distribution of blood types and genetic analyses in patients with rheumatic diseases are required.
